Stories about Opioid

Subscribe to Opioid

15.01.2021 – 15:15

Semdor Pharma Group

Merger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabis

more
16.12.2020 – 10:00

Grünenthal Group
Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development

Aachen (ots) - Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain. The Phase I trial will include 76 healthy participants. ...

more
29.09.2020 – 09:30

Medasense Biometrics Ltd
New Study: Postoperative Pain Can Be Reduced by Using NOL Monitoring to Guide Analgesic Medication During Surgery

Ramat Gan, Israel (ots/PRNewswire) - A new study has found that monitoring pain response levels during surgery with NOL technology (Medasense, Ramat Gan, Israel) can help reduce postoperative pain. Exploring the potential use of NOL monitoring to help enhance recovery after surgery, the study demonstrated that ...

more
18.12.2019 – 14:07

Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

more
20.02.2019 – 15:54

Alvogen
Alvogen Launches Generic Equivalent to Suboxone® (Buprenorphine/Naloxone) Sublingual Film

Pine Brook, New Jersey (ots/PRNewswire) - Global pharmaceutical company, Alvogen, has launched its generic equivalent to Suboxone® sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S., which will be available in 2mg/0.5 mg, 4mg/1mg, 8 mg/2mg, and 12 mg/3mg strengths. The launch took ...

more

1